These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Differential Response of Mycosis Fungoides Cells to Vorinostat. Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780 [TBL] [Abstract][Full Text] [Related]
25. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity. Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761 [TBL] [Abstract][Full Text] [Related]
26. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Cheriyath V; Kuhns MA; Kalaycio ME; Borden EC Br J Cancer; 2011 Mar; 104(6):957-67. PubMed ID: 21364585 [TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Namdar M; Perez G; Ngo L; Marks PA Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108 [TBL] [Abstract][Full Text] [Related]
28. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells. You BR; Han BR; Park WH Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148 [TBL] [Abstract][Full Text] [Related]
29. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969 [TBL] [Abstract][Full Text] [Related]
30. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance. Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759 [TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure. Qiu X; Rong X; Yang J; Lu Y BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701 [TBL] [Abstract][Full Text] [Related]
33. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Del Prete GQ; Shoemaker R; Oswald K; Lara A; Trubey CM; Fast R; Schneider DK; Kiser R; Coalter V; Wiles A; Wiles R; Freemire B; Keele BF; Estes JD; Quiñones OA; Smedley J; Macallister R; Sanchez RI; Wai JS; Tan CM; Alvord WG; Hazuda DJ; Piatak M; Lifson JD Antimicrob Agents Chemother; 2014 Nov; 58(11):6790-806. PubMed ID: 25182644 [TBL] [Abstract][Full Text] [Related]
34. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients. Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744 [TBL] [Abstract][Full Text] [Related]
35. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines. Hanke NT; Garland LL; Baker AF J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374 [TBL] [Abstract][Full Text] [Related]
36. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218 [TBL] [Abstract][Full Text] [Related]
37. Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Duvic M; Vu J Biologics; 2007 Dec; 1(4):377-92. PubMed ID: 19707308 [TBL] [Abstract][Full Text] [Related]
38. Alterations in histone acetylation following exposure to Tian XL; Lu X; Feng JB; Cai TJ; Li S; Tian M; Liu QJ Radiat Environ Biophys; 2018 Aug; 57(3):215-222. PubMed ID: 29774413 [TBL] [Abstract][Full Text] [Related]